RxDoctor Payments Data

Robert Keller, MD

Internal Medicine · Fort Worth, TXNPI 1962445346

Payments from drug & device makers

$25,851in general payments, 2019–2025

Across 707 payments — averaging $36.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • Novo Nordisk$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • GSK$2K
  • AstraZeneca$2K
  • Amgen$2K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$2,0758%
  • Speaking & faculty fees$4,00015%
  • Travel & lodging$350%
  • Food & beverage$19,69476%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer57$4,807
Novo Nordisk69$2,531
E.r. Squibb & Sons, L.L.C.7$2,289
GSK47$2,048
AstraZeneca48$1,949
Amgen57$1,888
AbbVie(2 entities)78$1,764
Lilly USA, LLC43$1,174
Boehringer Ingelheim36$743
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$470
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$450
Amarin Pharma, Inc.24$436
Phathom Pharmaceuticals, Inc.3$349
Johnson & Johnson17$347
Sanofi-aventis U.S. LLC8$326
Mylan Specialty L.p.9$276
Otsuka America Pharmaceutical, Inc.7$269
Bristol Myers Squibb5$267
Lundbeck LLC9$257
Bayer11$256
Axsome Therapeutics, Inc.7$237
Astellas Pharma US Inc7$215
Takeda Pharmaceuticals U.S.A., Inc.11$197
Almatica Pharma LLC9$195
Esperion Therapeutics, Inc.6$193
Dexcom, Inc.3$176
Althera Pharmaceuticals LLC5$163
Novartis9$144
Abbott7$142
Merck10$135
Portola Pharmaceuticals, LLC1$125
Gilead1$100
Sunovion Pharmaceuticals Inc.9$88
Sumitomo Pharma America, Inc.4$70
Antares Pharma, Inc.4$59
Teva Pharmaceuticals USA, Inc.4$54
Kowa Pharmaceuticals America, Inc.3$46
Azurity Pharmaceuticals, Inc.2$44
Ironwood Pharmaceuticals, Inc3$42
Viatris Specialty LLC2$39
Shire North American Group Inc3$38
Nestle Healthcare Nutrition Inc.2$35
Eisai Inc.2$34
Radius Health, Inc.2$33
Idorsia Pharmaceuticals US Inc2$32
Exact Sciences2$31
IBSA Pharma Inc.2$28
Sanofi Pasteur Inc.2$23
Nalpropion Pharmaceuticals LLC2$23
Pharmacosmos Therapeutics Inc.1$22
Zealand Pharma US, Inc.1$21
Protega Pharmaceutials Inc1$18
Vivus LLC2$18
Arbor Pharmaceuticals, Inc.1$17
Halozyme Inc1$16
Aytu Biopharma, Inc.1$16
BETA Bionics, Inc.1$16
Boston Scientific1$15
Si-bone, Inc.1$15
Mannkind Corporation1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,851 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$213,632
Medicare patients
338
Services billed
2,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$200,920
JardianceEmpagliflozin101$117,309
OzempicSemaglutide83$107,315
FarxigaDapagliflozin Propanediol77$96,719
ArexvyRsvpref3 Antigen/As01e/Pf112$35,097
MyrbetriqMirabegron26$30,073
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,034
LinzessLinaclotide20$19,988
Tresiba Flextouch U-100Insulin Degludec20$18,992
TrulicityDulaglutide13$18,278
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen555$18,198
SymbicortBudesonide/Formoterol Fumarate41$15,798
Boostrix TdapDiphth,pertuss(Acell),tet Vac207$14,444
XareltoRivaroxaban13$13,612
MounjaroTirzepatide13$13,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,807$200,920185 claims
Boehringer IngelheimJardiance$743$117,309101 claims
AstraZenecaFarxiga, Symbicort$1,949$112,517118 claims
Novo NordiskOzempic$2,531$107,31583 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta$2,048$76,401197 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$1,174$37,05338 claims
Astellas Pharma US IncMyrbetriq$215$30,07326 claims
AbbVieLinzess$1,764$19,98820 claims
Johnson & JohnsonXarelto$347$13,61213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →